H2020HORIZONFP7
Biokeralty Research Institute Aie
- Country
- ESSpain
- Defence projects
- 0
- Projects, all programmes
- 13
- As coordinator
- 0
- EU contribution (CORDIS)
- EUR 4,079,582
- Active
- 2012 to 2024
Projects
13 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| TUAITowards an Understanding of Artificial Intelligence via a transparent, open and explainable perspective | HORIZON | 2024 | Associated partner | EUR 0 |
| CARAMELCArdiovascular Risk Assessment in MEnopausaL women via multimodal data analysis enabling personalized prevention strategies | HORIZON | 2024 | Third party | Not stated |
| IN-ARMORTHERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO EFFECTIVELY COMBAT ANTIMICROBIAL RESISTANCE [IN-ARMOR] | HORIZON | 2023 | Participant | EUR 285,250 |
| IDEAL PhDIMDEA Nanociencia Doctoral Training Programme in Nanoscience | HORIZON | 2023 | Associated partner | EUR 0 |
| OPADEOptimise and predict antidepressant efficacy for patient with major depressive disorders using multi-omics analysis and AI-predictive tool | HORIZON | 2022 | Participant | EUR 252,500 |
| INNO4COV-19Boosting Innovation for COVID-19 Diagnostic, Prevention and Surveillance. | H2020 | 2020 | Participant | EUR 222,500 |
| REFINERegulatory Science Framework for Nano(bio)material-based Medical Products and Devices | H2020 | 2017 | Participant | EUR 102,395 |
| Smart-4-FabrySmart multifunctional GLA-nanoformulation for Fabry disease | H2020 | 2017 | Participant | EUR 533,325 |
| CLINGLIOA Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma. | H2020 | 2017 | Third party | Not stated |
| TAT-CFNovel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters | H2020 | 2016 | Participant | EUR 591,875 |
| NoCanTherNanomedicine upscaling for early clinical phases of multimodal cancer therapy | H2020 | 2016 | Participant | EUR 1,494,864 |
| THERAGLIOMicrobubble driven multimodal imaging and theranostics for gliomas | FP7 | 2013 | Participant | EUR 474,301 |
| BERENICEBenznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE | FP7 | 2012 | Participant | EUR 122,572 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.